1
|
Rex NB, McDonough RV, Ospel JM, Kashani N, Sehgal A, Fladt JC, McTaggart RA, Nogueira R, Menon B, Demchuk AM, Tymianski M, Hill MD, Goyal M. CT Perfusion Does Not Modify the Effect of Reperfusion in Patients with Acute Ischemic Stroke Undergoing Endovascular Treatment in the ESCAPE-NA1 Trial. AJNR Am J Neuroradiol 2023; 44:1045-1049. [PMID: 37620153 PMCID: PMC10494951 DOI: 10.3174/ajnr.a7954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 06/27/2023] [Indexed: 08/26/2023]
Abstract
BACKGROUND AND PURPOSE Although reperfusion is associated with improved outcomes in patients with acute ischemic stroke undergoing endovascular treatment, many patients still do poorly. We investigated whether CTP modifies the effect of near-complete reperfusion on clinical outcomes, ie, whether poor clinical outcomes despite near-complete reperfusion can be partly or fully explained by CTP findings. MATERIALS AND METHODS Data are from the Safety and Efficacy of Nerinetide in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1) trial. Admission CTP was processed using RAPID software, generating relative CBF and CBV volume maps at standard thresholds. CTP lesion volumes were compared in patients with-versus-without near-complete reperfusion. Associations between each CTP metric and clinical outcome (90-day mRS) were tested using multivariable logistic regression, adjusted for baseline imaging and clinical variables. Treatment-effect modification was assessed by introducing CTP lesion volume × reperfusion interaction terms in the models. RESULTS CTP lesion volumes and reperfusion status were available in 410/1105 patients. CTP lesion volumes were overall larger in patients without near-complete reperfusion, albeit not always statistically significant. Increased CBF <34%, CBV <34%, CBV <38%, and CBV <42% lesion volumes were associated with worse clinical outcome (ordinal mRS) at 90 days. CTP core lesion volumes did not modify the treatment effect of near-complete recanalization on clinical outcome. CONCLUSIONS CTP did not modify the effect of near-complete reperfusion on clinical outcomes. Thus, CTP cannot explain why some patients with near-complete reperfusion have poor clinical outcomes.
Collapse
Affiliation(s)
- N B Rex
- From the Department of Diagnostic Imaging (N.B.R., R.A.M.), Brown University, Providence, Rhode Island
- Department of Diagnostic Imaging (N.B.R., R.V.M., J.M.O., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
| | - R V McDonough
- Department of Diagnostic Imaging (N.B.R., R.V.M., J.M.O., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
| | - J M Ospel
- Department of Diagnostic Imaging (N.B.R., R.V.M., J.M.O., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
- Department of Clinical Neurosciences (J.M.O., A.S., J.C.F., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
| | - N Kashani
- Department of Neurosurgery (N.K.), University of Saskatchewan, Saskatoon, Saskatchewan, Canada
| | - A Sehgal
- Department of Clinical Neurosciences (J.M.O., A.S., J.C.F., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
| | - J C Fladt
- Department of Clinical Neurosciences (J.M.O., A.S., J.C.F., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
- Department of Neurology and Stroke Center (J.C.F.), University Hospital Basel, Basel, Switzerland
| | - R A McTaggart
- From the Department of Diagnostic Imaging (N.B.R., R.A.M.), Brown University, Providence, Rhode Island
| | - R Nogueira
- Department of Neurology and Neurosurgery (R.N.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - B Menon
- Department of Diagnostic Imaging (N.B.R., R.V.M., J.M.O., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
- Department of Clinical Neurosciences (J.M.O., A.S., J.C.F., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
| | - A M Demchuk
- Department of Diagnostic Imaging (N.B.R., R.V.M., J.M.O., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
- Department of Clinical Neurosciences (J.M.O., A.S., J.C.F., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
| | | | - M D Hill
- Department of Diagnostic Imaging (N.B.R., R.V.M., J.M.O., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
- Department of Clinical Neurosciences (J.M.O., A.S., J.C.F., B.M., A.M.D., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada
| | | |
Collapse
|
2
|
Kulkarni AV, Kumar K, Candia R, Arab JP, Tevethia HV, Premkumar M, Sharma M, Menon B, Rao GV, Reddy ND, Rao NP. Prophylactic Perioperative Terlipressin Therapy for Preventing Acute Kidney Injury in Living Donor Liver Transplant Recipients: A Systematic Review and Meta-Analysis. J Clin Exp Hepatol 2022; 12:417-427. [PMID: 35535072 PMCID: PMC9077193 DOI: 10.1016/j.jceh.2021.06.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Accepted: 06/18/2021] [Indexed: 12/12/2022] Open
Abstract
Background Acute kidney injury (AKI) is common in the perioperative transplant period and is associated with poor outcomes. Few studies reported a reduction in AKI incidence with terlipressin therapy by counteracting the hemodynamic alterations occurring during liver transplantation. However, the effect of terlipressin on posttransplant outcomes has not been systematically reviewed. Methods A comprehensive search of electronic databases was performed. Studies reporting the use of terlipressin in the perioperative period of living donor liver transplantation were included. We expressed the dichotomous outcomes as risk ratio (RR, 95% confidence interval [CI]) using the random effects model. The primary aim was to assess the posttransplant risk of AKI. The secondary aims were to assess the need for renal replacement therapy (RRT), vasopressors, effect on hemodynamics, blood loss during surgery, hospital and intensive care unit (ICU) stay, and in-hospital mortality. Results A total of nine studies reporting 711 patients (309 patients in the terlipressin group and 402 in the control group) were included for analysis. Terlipressin was administered for a mean duration of 53.44 ± 28.61 h postsurgery. The risk of AKI was lower with terlipressin (0.6 [95% CI, 0.44-0.8]; P = 0.001). However, on sensitivity analysis including only four randomized controlled trials (I2 = 0; P = 0.54), the risk of AKI was similar in both the groups (0.7 [0.43-1.09]; P = 0.11). The need for RRT was similar in both the groups (0.75 [0.35-1.56]; P = 0.44). Terlipressin therapy reduced the need for another vasopressor (0.34 [0.25-0.47]; P < 0.001) with a concomitant rise in mean arterial pressure and systemic vascular resistance by 3.2 mm Hg (1.64-4.7; P < 0.001) and 77.64 dyne cm-1.sec-5 (21.27-134; P = 0.007), respectively. Blood loss, duration of hospital/ICU stay, and mortality were similar in both groups. Conclusions Perioperative terlipressin therapy has no clinically relevant benefit.
Collapse
Key Words
- AKI, acute kidney injury
- BMI, body mass index
- BUN, blood urea nitrogen
- C, control
- CI, confidence interval
- CNI, calcineurin inhibitors
- CTP, Child-Turcotte-Pugh score
- DDLT, deceased donor liver transplantation
- GRWR, graft-torecipient weight ratio
- HCC, hepatocellular carcinoma
- HCV, hepatitis C virus
- HRS, hepatorenal syndrome
- ICU, intensive care unit
- LDLT, living donor liver transplantation
- MAP, mean arterial pressure
- MELD, model for end-stage liver disease
- NR, not reported
- PRBC, packed red blood cells
- RCT, randomized controlled trial
- RRT, renal replacement therapy
- SD, standard deviation
- SVR, systemic vascular resistance
- Tp, Terlipressin
- acute kidney injury
- hemodynamics
- mTORi, mammalian target of rapamycin inhibitors
- portal hypertension
- renal replacement therapy
- sCr, serum creatinine
- vasoconstrictors
Collapse
Affiliation(s)
- Anand V. Kulkarni
- Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India,Address for correspondence. Dr. Anand V.Kulkarni, Department of Hepatology and Liver Transplantation, Asian Institute of Gastroenterology, Hyderabad, India.
| | - Karan Kumar
- Department of Hepatology, Pacific Institute of Medical Sciences, Udaipur, India
| | - Roberto Candia
- Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile
| | - Juan P. Arab
- Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile
| | - Harsh V. Tevethia
- Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India
| | | | - Mithun Sharma
- Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India
| | - Balachandandran Menon
- Department of Hepatobiliary Surgery and Liver Transplantation, Asian Institute of Gastroenterology, Hyderabad, India
| | - Guduru V. Rao
- Department of Hepatobiliary Surgery and Liver Transplantation, Asian Institute of Gastroenterology, Hyderabad, India
| | - Nageshwar D Reddy
- Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India
| | - Nagaraja P. Rao
- Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India
| |
Collapse
|
3
|
Sharma M, Menon B, Manam G. Hypoglycemic hemiparesis as stroke mimic with transient splenial lesion and internal capsule involvement: A reversible clinico-radiological concurrence. J Postgrad Med 2022; 68:109-111. [PMID: 35466663 PMCID: PMC9196292 DOI: 10.4103/jpgm.jpgm_817_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Hypoglycemia presents with a spectrum of neurological manifestations ranging from lightheadedness to confusion and coma. We report here the case of a 61-year-old woman with right hemiparesis presenting within the window period for stroke thrombolysis. MRI brain showed diffusion restriction in posterior limb of left internal capsule and splenium. Patient had documented hypoglycemia of 38 mg/dL. Patient's hemiparesis resolved after glucose correction, and radiological findings completely resolved after 10 days. We present this case to highlight the rare radiological finding of simultaneous internal capsule and splenium involvement in hypoglycemic hemiparesis and the importance to rule out stroke mimics to avoid unwanted thrombolysis.
Collapse
|
4
|
Nathan J, Hughes C, Patel S, Mathew L, Smith C, Pink A, Woolf R, Menon B, Kirkham LB. AB0573 DUPILUMAB-INDUCED ENTHESITIS/ARTHRITIS IN PATIENTS WITH ATOPIC DERMATITIS: A RETROSPECTIVE OBSERVATIONAL STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1363] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Atopic dermatitis (AD) is a common skin condition with a prevalence of 2–10% in adults1. IL-4 and IL-13 play a key role in the pathogenesis. Dupilumab, a human IgG4 monoclonal antibody binding the alpha subunit of the IL-4 receptor, blocking IL-4 and IL-13 signaling, has important efficacy in this difficult to treat disease. We first reported a musculoskeletal (MSK) adverse effect of enthesis/arthritis developing in 3 patients in 20192.Objectives:To report the ongoing experience at our centre of this new clinical paradigm, incidence and patient progress including clinical presentation, imaging and management.Methods:Clinical and radiological data was collected from electronic case records of all cases presenting with features of enthesitis/arthritis between October 2018 and January 2021.Results:Since initiation of dupilumab at GSTT, approximately 400 adults with moderate-to-severe AD have received at least one dose. Of these, 23 patients (14 men, 9 women) had the clinical syndrome of inflammatory enthesitis/tenosynovitis/arthritis. Nine patients had both enthesitis and arthritis, 10 enthesitis, 3 enthesitis and tenosynovitis and 1 arthritis only. Four of these also reported new onset inflammatory back pain symptoms. None had a preceding history of arthritis or enthesitis. Median onset of symptoms following initiation of dupilumab was 4 months. However, onset of symptoms ranged between 2 weeks and 48 months. Imaging (US/MRI) was performed in 18 patients, 11 with Doppler US positive enthesitis confirming clinical findings. Most common sites were lateral epicondyles, achilles and patella tendons. Two patients with more disabling symptoms had MRI confirmed gluteus medius and hamstring enthesitis and arthritis. Spine and SI joint MRI in 4 patients was negative. Most patients had normal inflammatory markers except 2; CRP 117, ESR 96 and CRP 13, ESR 10. All patients had very good AD response to dupilumab, average EASI score before and after Dupilumab was 21 and 4.2 respectively. One patient developed skin manifestations of guttate psoriasis, with subsequent disabling arthritis/enthesitis. Due to the life-changing beneficial effect of dupilumab therapy most patients did not want to stop therapy. We used NSAID therapy, etoricoxib/celecoxib/naproxen for symptom relief which was usually partly effective allowing continuation of dupilumab treatment in most. Five patients with severe MSK symptoms stopped Dupilumab completely. Some patients temporarily paused therapy but re-started as their AD became worse, often changing from the usual 2 weekly to 4 weekly dosing. Most patients continuing dupilumab had persistent MSK symptoms. Four patients who stopped dupilumab were treated with baricitinib, which has potential efficacy for both MSK symptoms and AD. Two did not tolerate it and remained on NSAID therapy.Conclusion:These data further characterize a new syndrome of enthesitis and/or arthritis induced by Dupilumab. In those with mild MSK symptoms use of NSAIDs allows continuation of full-dose dupilumab, in moderate cases reducing dupilumab dose frequency plus NSAID therapy maintains function. Most patients had on-going MSK symptoms. In more severe cases JAKi therapy may be an effective strategy. Our initial hypothesis that inhibition of IL-4/13 by dupilumab triggers an IL-17/23/TNF-mediated inflammatory MSK syndrome in some patients is supported by a recent in vitro study3.References:[1]Beck L et al. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. July 10, 2014. N Engl J Med 2014; 371:130-139[2]Willsmore ZN et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol 2019; 0. doi:10.1111/bjd.18031.[3]Bridegwood C et al. Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy. Rheumatology (Oxford). 2020 Nov 30:keaa568. doi: 10.1093/rheumatology/keaa568Disclosure of Interests:Joseph Nathan: None declared., Catherine Hughes Speakers bureau: Presented for Abbvie, Samir Patel: None declared., Libin Mathew: None declared., Catherine Smith Grant/research support from: Grants/research support; Professor Smith is a PI/CoPI on a number of commercially supported studie (Abbvie, Janssen, Leo, Sanofi)., Andrew Pink Paid instructor for: Speaker or advisor to Lilly, Abbvie, Sanofi, Leo, Almirall, Novartis, Janssen, UCB, Galderma, BMS, La-Roche Posay, Richard Woolf: None declared., Bina Menon Speakers bureau: Presented for Abbvie, L Bruce Kirkham Grant/research support from: Professor Kirkham has received honoraria and/or research funding from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer and UCB.
Collapse
|
5
|
Sears AV, Woolf RT, Gribaleva E, Abdelrahman W, Robbie S, Menon B, Kirkham B, Smith CH, Pink AE. Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated. Br J Dermatol 2020; 184:755-757. [PMID: 33107978 DOI: 10.1111/bjd.19631] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 10/21/2020] [Accepted: 10/25/2020] [Indexed: 12/31/2022]
Affiliation(s)
- A V Sears
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - R T Woolf
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - E Gribaleva
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.,I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - W Abdelrahman
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - S Robbie
- Department of Ophthalmology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - B Menon
- Department of Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - B Kirkham
- Department of Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - C H Smith
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.,St John's Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK
| | - A E Pink
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| |
Collapse
|
6
|
Hughes C, Menon B, Woolf R, Willsmore Z, Smith C, Pink A, Kirkham LB. SAT0376 DOES SUPPRESSION OF IL-4 AND IL-13 LEAD TO THE DEVELOPMENT OF NEW ONSET SPONDYLO-ARTHRITIS IN SUSCEPTIBLE PATIENTS? Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Enthesitis is a key feature of peripheral Spondyloarthritis (SpA). Several pro-inflammatory cytokines including Interleukin-17 and Interleukin-23 are found within the enthesis (1). Dupilumab is a recombinant human monoclonal antibody that inhibits signalling of Interleukin-4 and Interleukin-13, approved for use in patients with moderate- to –severe atopic eczema. Here we describe a cohort of patients with severe atopic eczema who have developed a new peripheral SpA/ enthesitis after receiving Dupilumab.Objectives:To describe the clinical and imaging details of this cohort.Methods:All patients in St John’s Institute of Dermatology who exhibited new arthralgias on Dupilumab therapy were referred for assessment in Guy’s Rheumatology Department. These patients had a focussed history, examination, ultrasound and/or MRI of affected joints and entheseal sites.Results:To date we have seen 12 patients with a history of new inflammatory peripheral SpA type symptoms following onset of Dupilumab therapy. There were 7 males and 5 females all of whom have longstanding severe atopic Eczema. All patients had raised baseline IgE levels of mainly >10000. All patients exhibited a positive response to Dupilumab with a marked improvement in eczema as measured by the EASI score. All patients had normal inflammatory markers and negative immunological screening bloods. Musculoskeletal symptom onset was between 2 and 20 weeks after starting treatment. Typically, these patients had inflammatory symptoms affecting both the small joints and the entheseal sites. 2/12 patients developed inflammatory sounding spinal pain. 2/12 patients had ultrasound evidence of arthritis. 11/12 patients had radiological findings of enthesitis as seen on MRI or ultrasound (power doppler ultrasound signal). 9/12 patients were treated with non-steroidal anti-inflammatories with variable improvement.1 patient required no treatment and 1 patient received low dose prednisolone.Conclusion:In our centre approximately 200 patients have received Dupilumab. These musculoskeletal findings have not been reported previously in clinical trials. We hypothesise that the profound inhibition of IL- 4/13 may allow an inflammatory response at the enthesis presenting with a peripheral SpA pattern. IL-4 has been shown to suppress delayed type hypersensitivity reactions (DTHRs) and psoriasis in both human and mice studies (2). These findings and the demonstratation that IL-23 transcription and secretion can be suppressed by IL-4 with resultant reduction in Th17 function (3) may be key factors as to why a SpA type response is seen in certain subjects.References:[1]Bridgewood et al. Immunol Rev 2020 [Epub][2]Ghoreschi et al. Nat Med. 2003;9:40-6.[3]Guenova et al. PNAS. 2015;112:2163-8.Disclosure of Interests:Catherine Hughes Speakers bureau: Lilly, Bina Menon Speakers bureau: Novartis, Richard Woolf: None declared, Zena Willsmore: None declared, Catherine Smith: None declared, Andrew Pink: None declared, L Bruce Kirkham Grant/research support from: Eli Lilly Novartis, Consultant of: Eli Lilly Gilead Janssen Novartis
Collapse
|
7
|
Menon B, Pasupuleti S. Poor awareness of role of helmet to prevent head injury. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Menon B, Ramalingam K. Reproductive endocrine functions in women with epilepsy. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
|
10
|
Menon B. Towards a new model of understanding-the triple network, psychopathology, phenomenology and the structure of the mind. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.1625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Willsmore Z, Woolf R, Hughes C, Menon B, Kirkham B, Smith C, Pink A. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol 2019; 181:1068-1070. [DOI: 10.1111/bjd.18031] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Z.N. Willsmore
- St. John's Institute of Dermatology Guy's and St. Thomas’ Hospital NHS Trust GLondon U.K
| | - R.T. Woolf
- St. John's Institute of Dermatology Guy's and St. Thomas’ Hospital NHS Trust GLondon U.K
| | - C. Hughes
- Department of Rheumatology Guy's and St. Thomas’ Hospital NHS Trust GLondon U.K
| | - B. Menon
- Department of Rheumatology Guy's and St. Thomas’ Hospital NHS Trust GLondon U.K
| | - B. Kirkham
- Department of Rheumatology Guy's and St. Thomas’ Hospital NHS Trust GLondon U.K
| | - C.H. Smith
- St. John's Institute of Dermatology Guy's and St. Thomas’ Hospital NHS Trust GLondon U.K
| | - A.E. Pink
- St. John's Institute of Dermatology Guy's and St. Thomas’ Hospital NHS Trust GLondon U.K
| |
Collapse
|
12
|
Kably M, Menon B, Richardson A, Bhatia S. 03:45 PM Abstract No. 127 Bladder artery embolization (BAE) in refractory vesical hematuria of malignant origin. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
13
|
Casian A, Sangle (joint first author) S, Malaiya R, Lutalo P, Nel L, Menon B, Verma H, Stanford M, D'Cruz D. SAT0342 Features of Orbital Inflammatory Disease and Response To Immunosuppressive Therapy. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Vagal A, Foster LD, Menon B, Livorine A, Shi J, Qazi E, Yeatts SD, Demchuk AM, Hill MD, Tomsick TA, Goyal M. Multimodal CT Imaging: Time to Treatment and Outcomes in the IMS III Trial. AJNR Am J Neuroradiol 2016; 37:1393-8. [PMID: 26988811 DOI: 10.3174/ajnr.a4751] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Accepted: 01/22/2016] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE The importance of time in acute stroke is well-established. Using the Interventional Management of Stroke III trial data, we explored the effect of multimodal imaging (CT perfusion and/or CT angiography) versus noncontrast CT alone on time to treatment and outcomes. MATERIALS AND METHODS We examined 3 groups: 1) subjects with baseline CTP and CTA (CTP+CTA), 2) subjects with baseline CTA without CTP (CTA), and 3) subjects with noncontrast head CT alone. The demographics, treatment time intervals, and clinical outcomes in these groups were studied. RESULTS Of 656 subjects enrolled in the Interventional Management of Stroke III trial, 90 (13.7%) received CTP and CTA, 216 (32.9%) received CTA (without CTP), and 342 (52.1%) received NCCT alone. Median times for the CTP+CTA, CTA, and NCCT groups were as follows: stroke onset to IV tPA (120.5 versus 117.5 versus 120 minutes; P = .5762), IV tPA to groin puncture (77.5 versus 81 versus 91 minutes; P = .0043), groin puncture to endovascular therapy start (30 versus 38 versus 44 minutes; P = .0001), and endovascular therapy start to end (63 versus 46 versus 74 minutes; P < .0001). Compared with NCCT, the CTA group had better outcomes in the endovascular arm (OR, 2.12; 95% CI, 1.36-3.31; adjusted for age, NIHSS score, and time from onset to IV tPA). The CTP+CTA group did not have better outcomes compared with the NCCT group. CONCLUSIONS Use of CTA with or without CTP did not delay IV tPA or endovascular therapy compared with NCCT in the Interventional Management of Stroke III trial.
Collapse
Affiliation(s)
- A Vagal
- From the Department of Radiology (A.V., A.L., J.S., T.A.T.), University of Cincinnati Medical Center, Cincinnati, Ohio
| | - L D Foster
- Department of Public Health Sciences (L.D.F., S.D.Y.), Medical University of South Carolina, Charleston, South Carolina
| | - B Menon
- Radiology (B.M, E.Q., M.G.), University of Calgary, Calgary Alberta, Canada
| | - A Livorine
- From the Department of Radiology (A.V., A.L., J.S., T.A.T.), University of Cincinnati Medical Center, Cincinnati, Ohio
| | - J Shi
- From the Department of Radiology (A.V., A.L., J.S., T.A.T.), University of Cincinnati Medical Center, Cincinnati, Ohio
| | - E Qazi
- Radiology (B.M, E.Q., M.G.), University of Calgary, Calgary Alberta, Canada
| | - S D Yeatts
- Department of Public Health Sciences (L.D.F., S.D.Y.), Medical University of South Carolina, Charleston, South Carolina
| | | | - M D Hill
- Departments of Neurology (A.M.D., M.D.H.)
| | - T A Tomsick
- From the Department of Radiology (A.V., A.L., J.S., T.A.T.), University of Cincinnati Medical Center, Cincinnati, Ohio
| | - M Goyal
- Radiology (B.M, E.Q., M.G.), University of Calgary, Calgary Alberta, Canada
| |
Collapse
|
15
|
Yoo A, Zaidat O, Chaudhry Z, Berkhemer O, González R, Goyal M, Demchuk A, Menon B, Mualem E, Buell H, Kuo S, Sit S, Bose A. O-006 using sequential and post-procedure aspects as predictors of good clinical outcome after intra-arterial therapy for acute ischemic stroke. J Neurointerv Surg 2015. [DOI: 10.1136/neurintsurg-2015-011917.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, Thorpe KE, Aviv R, Boyle K, Blakely J, Cote R, Hall J, Kapral M, Kozlowski N, Laupacis A, O’Donnell M, Sabihuddin K, Sharma M, Shuaib A, Vaid H, Pinter A, Abootalebi S, Chan R, Crann S, Fleming L, Frank C, Hachinski V, Hesser K, Kumar B, Soros P, Wright M, Basile V, Boyle K, Hopyan J, Rajmohan Y, Swartz R, Vaid H, Valencia G, Ween J, Aram H, Barber P, Coutts S, Demchuk A, Fischer K, Hill M, Klein G, Kenney C, Menon B, McClelland M, Russell A, Ryckborst K, Stys P, Smith E, Watson T, Chacko S, Sahlas D, Sancan J, Côté R, Durcan L, Ehrensperger E, Minuk J, Wein T, Wadup L, Asdaghi N, Beckman J, Esplana N, Masigan P, Murphy C, Tang E, Teal P, Villaluna K, Woolfenden A, Yip S, Bussière M, Dowlatshahi D, Sharma M, Stotts G, Robert S, Ford K, Hackam D, Miners L, Mabb T, Spence JD, Buck B, Griffin-Stead T, Jassal R, Siddiqui M, Hache A, Lessard C, Lebel F, Mackey A, Verreault S, Astorga C, Casaubon LK, del Campo M, Jaigobin C, Kalman L, Silver FL, Atkins L, Coles K, Penn A, Sargent R, Walter C, Gable Y, Kadribasic N, Schwindt B, Shuaib A, Kostyrko P, Selchen D, Saposnik G, Christie P, Jin A, Hicklin D, Howse D, Edwards E, Jaspers S, Sher F, Stoger S, Crisp D, Dhanani A, John V, Levitan M, Mehdiratta M, Wong D. Atrial Premature Beats Predict Atrial Fibrillation in Cryptogenic Stroke. Stroke 2015; 46:936-41. [DOI: 10.1161/strokeaha.115.008714] [Citation(s) in RCA: 132] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- David J. Gladstone
- From the Division of Neurology (D.J.G.), Department of Medicine (D.J.G., P.D., M.S., M.M.), and Dalla Lana School of Public Health (K.E.T.), University of Toronto, Toronto, Ontario, Canada; University of Toronto Stroke Program, Toronto, Ontario, Canada (D.J.G.); Division of Neurology, Department of Medicine, and the Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada (D.J.G.); Heart and Stroke Foundation Canadian Partnership for
| | - Paul Dorian
- From the Division of Neurology (D.J.G.), Department of Medicine (D.J.G., P.D., M.S., M.M.), and Dalla Lana School of Public Health (K.E.T.), University of Toronto, Toronto, Ontario, Canada; University of Toronto Stroke Program, Toronto, Ontario, Canada (D.J.G.); Division of Neurology, Department of Medicine, and the Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada (D.J.G.); Heart and Stroke Foundation Canadian Partnership for
| | - Melanie Spring
- From the Division of Neurology (D.J.G.), Department of Medicine (D.J.G., P.D., M.S., M.M.), and Dalla Lana School of Public Health (K.E.T.), University of Toronto, Toronto, Ontario, Canada; University of Toronto Stroke Program, Toronto, Ontario, Canada (D.J.G.); Division of Neurology, Department of Medicine, and the Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada (D.J.G.); Heart and Stroke Foundation Canadian Partnership for
| | - Val Panzov
- From the Division of Neurology (D.J.G.), Department of Medicine (D.J.G., P.D., M.S., M.M.), and Dalla Lana School of Public Health (K.E.T.), University of Toronto, Toronto, Ontario, Canada; University of Toronto Stroke Program, Toronto, Ontario, Canada (D.J.G.); Division of Neurology, Department of Medicine, and the Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada (D.J.G.); Heart and Stroke Foundation Canadian Partnership for
| | - Muhammad Mamdani
- From the Division of Neurology (D.J.G.), Department of Medicine (D.J.G., P.D., M.S., M.M.), and Dalla Lana School of Public Health (K.E.T.), University of Toronto, Toronto, Ontario, Canada; University of Toronto Stroke Program, Toronto, Ontario, Canada (D.J.G.); Division of Neurology, Department of Medicine, and the Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada (D.J.G.); Heart and Stroke Foundation Canadian Partnership for
| | - Jeff S. Healey
- From the Division of Neurology (D.J.G.), Department of Medicine (D.J.G., P.D., M.S., M.M.), and Dalla Lana School of Public Health (K.E.T.), University of Toronto, Toronto, Ontario, Canada; University of Toronto Stroke Program, Toronto, Ontario, Canada (D.J.G.); Division of Neurology, Department of Medicine, and the Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada (D.J.G.); Heart and Stroke Foundation Canadian Partnership for
| | - Kevin E. Thorpe
- From the Division of Neurology (D.J.G.), Department of Medicine (D.J.G., P.D., M.S., M.M.), and Dalla Lana School of Public Health (K.E.T.), University of Toronto, Toronto, Ontario, Canada; University of Toronto Stroke Program, Toronto, Ontario, Canada (D.J.G.); Division of Neurology, Department of Medicine, and the Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada (D.J.G.); Heart and Stroke Foundation Canadian Partnership for
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - R. Chan
- London Health Sciences Centre; London, Ontario
| | - S. Crann
- London Health Sciences Centre; London, Ontario
| | - L. Fleming
- London Health Sciences Centre; London, Ontario
| | - C. Frank
- London Health Sciences Centre; London, Ontario
| | | | - K. Hesser
- London Health Sciences Centre; London, Ontario
| | - B.S. Kumar
- London Health Sciences Centre; London, Ontario
| | - P. Soros
- London Health Sciences Centre; London, Ontario
| | - M. Wright
- London Health Sciences Centre; London, Ontario
| | - V. Basile
- Sunnybrook Health Sciences Centre; Toronto, Ontario
| | - K. Boyle
- Sunnybrook Health Sciences Centre; Toronto, Ontario
| | - J. Hopyan
- Sunnybrook Health Sciences Centre; Toronto, Ontario
| | - Y. Rajmohan
- Sunnybrook Health Sciences Centre; Toronto, Ontario
| | - R. Swartz
- Sunnybrook Health Sciences Centre; Toronto, Ontario
| | - H. Vaid
- Sunnybrook Health Sciences Centre; Toronto, Ontario
| | - G. Valencia
- Sunnybrook Health Sciences Centre; Toronto, Ontario
| | - J. Ween
- Sunnybrook Health Sciences Centre; Toronto, Ontario
| | - H. Aram
- Foothills Hospital; Calgary, Alberta
| | | | - S. Coutts
- Foothills Hospital; Calgary, Alberta
| | | | | | - M.D. Hill
- Foothills Hospital; Calgary, Alberta
| | - G. Klein
- Foothills Hospital; Calgary, Alberta
| | - C. Kenney
- Foothills Hospital; Calgary, Alberta
| | - B. Menon
- Foothills Hospital; Calgary, Alberta
| | | | | | | | - P. Stys
- Foothills Hospital; Calgary, Alberta
| | | | | | - S. Chacko
- Hamilton Health Sciences Centre; Hamilton, Ontario
| | - D. Sahlas
- Hamilton Health Sciences Centre; Hamilton, Ontario
| | - J. Sancan
- Hamilton Health Sciences Centre; Hamilton, Ontario
| | - R. Côté
- Montreal General Hospital; Montreal, Québec
| | - L. Durcan
- Montreal General Hospital; Montreal, Québec
| | | | - J. Minuk
- Montreal General Hospital; Montreal, Québec
| | - T. Wein
- Montreal General Hospital; Montreal, Québec
| | - L. Wadup
- Montreal General Hospital; Montreal, Québec
| | - N. Asdaghi
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - J. Beckman
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - N. Esplana
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - P. Masigan
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - C. Murphy
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - E. Tang
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - P. Teal
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - K. Villaluna
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - A. Woolfenden
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | - S. Yip
- Vancouver Hospital and Health Sciences Centre; Vancouver, British Columbia
| | | | | | - M. Sharma
- The Ottawa Hospital; Ottawa, Ontario
| | - G. Stotts
- The Ottawa Hospital; Ottawa, Ontario
| | - S. Robert
- The Ottawa Hospital; Ottawa, Ontario
| | - K. Ford
- Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute; London, Ontario
| | - D. Hackam
- Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute; London, Ontario
| | - L. Miners
- Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute; London, Ontario
| | - T. Mabb
- Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute; London, Ontario
| | - J. D. Spence
- Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute; London, Ontario
| | - B. Buck
- Grey Nuns Hospital; Edmonton Alberta
| | | | - R. Jassal
- Grey Nuns Hospital; Edmonton Alberta
| | | | - A. Hache
- Centre Hospitalier Affilié Universitaire de Québec: Hôpital de l’Enfant-Jesus; Québec, Québec
| | - C. Lessard
- Centre Hospitalier Affilié Universitaire de Québec: Hôpital de l’Enfant-Jesus; Québec, Québec
| | - F. Lebel
- Centre Hospitalier Affilié Universitaire de Québec: Hôpital de l’Enfant-Jesus; Québec, Québec
| | - A. Mackey
- Centre Hospitalier Affilié Universitaire de Québec: Hôpital de l’Enfant-Jesus; Québec, Québec
| | - S. Verreault
- Centre Hospitalier Affilié Universitaire de Québec: Hôpital de l’Enfant-Jesus; Québec, Québec
| | - C. Astorga
- University Health Network; Toronto, Ontario
| | | | | | | | - L. Kalman
- University Health Network; Toronto, Ontario
| | - FL Silver
- University Health Network; Toronto, Ontario
| | - L. Atkins
- Vancouver Island Health Authority; Victoria, British Columbia
| | - K. Coles
- Vancouver Island Health Authority; Victoria, British Columbia
| | - A. Penn
- Vancouver Island Health Authority; Victoria, British Columbia
| | - R. Sargent
- Vancouver Island Health Authority; Victoria, British Columbia
| | - C. Walter
- Vancouver Island Health Authority; Victoria, British Columbia
| | - Y. Gable
- Mackenzie Health Sciences Centre; Edmonton, Alberta
| | | | - B. Schwindt
- Mackenzie Health Sciences Centre; Edmonton, Alberta
| | - A. Shuaib
- Mackenzie Health Sciences Centre; Edmonton, Alberta
| | | | - D. Selchen
- St. Michael’s Hospital; Toronto, Ontario
| | | | - P. Christie
- Kingston General Hospital; Kingston, Ontario
| | - A. Jin
- Kingston General Hospital; Kingston, Ontario
| | - D. Hicklin
- Thunder Bay Regional Health Sciences Centre; Thunder Bay, Ontario
| | - D. Howse
- Thunder Bay Regional Health Sciences Centre; Thunder Bay, Ontario
| | - E. Edwards
- Thunder Bay Regional Health Sciences Centre; Thunder Bay, Ontario
| | - S. Jaspers
- Thunder Bay Regional Health Sciences Centre; Thunder Bay, Ontario
| | - F. Sher
- Thunder Bay Regional Health Sciences Centre; Thunder Bay, Ontario
| | - S. Stoger
- Thunder Bay Regional Health Sciences Centre; Thunder Bay, Ontario
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Kannan V, Misra BK, Kapadia A, Bajpai R, Deshpande S, Almel S, Sankhe M, Desai K, Shaikh M, Anand V, Kannan A, Teo WY, Ross J, Bollo R, Seow WT, Tan AM, Kang SG, Kim DS, Li XN, Lau CC, Mohila CA, Adesina A, Su J, Ichimura K, Fukushima S, Matsushita Y, Tomiyama A, Niwa T, Suzuki T, Nakazato Y, Mukasa A, Kumabe T, Nagane M, Iuchi T, Mizoguchi M, Tamura K, Sugiyama K, Nakada M, Kanemura Y, Yokogami K, Matsutani M, Shibata T, Nishikawa R, Takami H, Fukushima S, Fukuoka K, Yanagisawa T, Nakamura T, Arita H, Narita Y, Shibui S, Nishikawa R, Ichimura K, Matsutani M, Sands S, Guerry W, Kretschmar C, Donahue B, Allen J, Matsutani M, Nishikawa R, Kumabe T, Sugiyama K, Nakamura H, Sawamura Y, Fujimaki T, Hattori E, Arakawa Y, Kawabata Y, Aoki T, Miyamoto S, Kagawa N, Hirayama R, Fujimoto Y, Chiba Y, Kinoshita M, Takano K, Eino D, Fukuya S, Nakanishi K, Yamamoto F, Hashii Y, Hashimoto N, Hara J, Yoshimine T, Murray M, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson J, Sumerauer D, Zapotocky M, Churackova M, Cyprova S, Zamecnik J, Malinova B, Kyncl M, Tichy M, Stary J, Lassen-Ramshad Y, von Oettingen G, Agerbaek M, Ohnishi T, Kohno S, Inoue A, Ohue S, Kohno S, Iwata S, Inoue A, Ohue S, Kumon Y, Ohnishi T, Acharya S, DeWees T, Shinohara E, Perkins S, Kato H, Fuji H, Nakasu Y, Ishida Y, Okawada S, Yang Q, Guo C, Chen Z, Alapetite C, Faure-Conter C, Verite C, Pagnier A, Laithier V, Entz-Werle N, Gorde-Grosjean S, Palenzuela G, Lemoine P, Frappaz D, Nguyen HA, Bui L, Ngoc, Cerbone M, Ederies A, Losa L, Moreno C, Sun K, Spoudeas HA, Nakano Y, Okada K, Kosaka Y, Nagashima T, Hashii Y, Kagawa N, Soejima T, Osugi Y, Sakamoto H, Hara J, Nicholson J, Alapetite C, Kortmann RD, Garre ML, Ricardi U, Saran F, Frappaz D, Calaminus G, Muda Z, Menon B, Ibrahim H, Rahman EJA, Muhamad M, Othman IS, Thevarajah A, Cheng S, Kilday JP, Laperriere N, Drake J, Bouffet E, Bartels U, Sakamoto H, Matsusaka Y, Watanabe Y, Umaba R, Hara J, Osugi Y, Alapetite C, Ruffier-Loubiere A, De Marzi L, Bolle S, Claude L, Habrand JL, Brisse H, Frappaz D, Doz F, Bourdeaut F, Dendale R, Mazal A, Fournier-Bidoz N, Fujimaki T, Fukuoka K, Shirahata M, Suzuki T, Adachi JI, Mishima K, Wakiya K, Matsutani M, Nishikawa R, Fukushima S, Yamashita S, Kato M, Nakamura H, Takami H, Suzuki T, Yanagisawa T, Mukasa A, Kumabe T, Nagane M, Sugiyama K, Tamura K, Narita Y, Shibui S, Shibata T, Ushijima T, Matsutani M, Nishikawa R, Ichimura K, Consortium IGA, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Czech T, Nicholson J, Frappaz D, Kortmann RD, Alapetite C, Garre ML, Ricardi U, Saran F, Calaminus G, Hayden J, Bartels U, Calaminus G, Joseph R, Nicholson J, Hale J, Lindsay H, Kogiso M, Qi L, Yee TW, Huang Y, Mao H, Lin F, Baxter P, Su J, Terashima K, Perlaky L, Lau C, Parsons D, Chintagumpala M, Li XAN, Osorio D, Vaughn D, Gardner S, Mrugala M, Ferreira M, Keene C, Gonzalez-Cuyar L, Hebb A, Rockhill J, Wang L, Yamaguchi S, Burstein M, Terashima K, Ng HK, Nakamura H, He Z, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adesina A, Sun J, Munzy D, Gibbs R, Leal S, Wheeler D, Lau C, Dhall G, Robison N, Judkins A, Krieger M, Gilles F, Park J, Lee SU, Kim T, Choi Y, Park HJ, Shin SH, Kim JY, Robison N, Dhir N, Khamani J, Margol A, Wong K, Britt B, Evans A, Nelson M, Grimm J, Finlay J, Dhall G. GERM CELL TUMOURS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Soin AS, Mohanka R, Saraf N, Rastogi A, Goja S, Menon B, Vohra V, Saigal S, Sud R, Kumar D, Bhangui P, Ramachandra S, Singla P, Shetty G, Raghvendra K, Elmagd KMA. India's first successful intestinal transplant: the road traveled and the lessons learnt. Indian J Gastroenterol 2014; 33:104-13. [PMID: 24500752 DOI: 10.1007/s12664-013-0437-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2013] [Accepted: 12/14/2013] [Indexed: 02/04/2023]
Abstract
Intestinal transplant is a therapeutic challenge not just surgically but also logistically because of the multidisciplinary expertise and resources required. A large proportion of patients who undergo massive bowel resection and develop intestinal failure have poor outcome, because of inability to sustain long-term parenteral nutrition and limited availability of intestinal and multi-visceral transplantation facilities. We report the first successful isolated intestinal transplant from India.
Collapse
Affiliation(s)
- A S Soin
- Medanta Institute of Liver Diseases and Transplantation, Medanta-The Medicity, Sector 38, Gurgaon, Haryana, 122 001, India,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Combined pulmonary fibrosis and emphysema (CPFE) syndrome is an uncommon entity characterised by emphysema of the upper lobes and diffuse fibrosis of the lower lobes and carries a bad prognosis with the onset of pulmonary hypertension. Lung involvement due to exposures suffered by welders is generally considered benign though, rarely, a diffuse interstitial fibrotic disease has been reported. CPFE syndrome has however never been reported in welders. A 65-year-old man, welder by occupation and an ex-smoker, presented with progressive exertional dyspnoea associated with dry cough noticed for the last four months. On examination, there was mild tachypnea, clubbing and bilateral basal velcro crepitations on chest auscultation. Lung function test revealed mild mixed ventilatory impairment with severe diffusion defect. HRCT chest showed bilateral upper lobe emphysema and diffuse interstitial fibrosis in the lower lobes. Transbronchial lung biopsy revealed interstitial fibrosis, chronic inflammation and iron deposits. A diagnosis of combined pulmonary fibrosis with emphysema (CPFE) with interstitial pulmonary siderofibrosis (IPS) was established. A review of literature did not show any other report of a similar nature.
Collapse
Affiliation(s)
- R Roshan
- Department of Cardiorespiratory Physiology, Vallabhbhai Patel Chest Institute, Delhi, India
| | | | | | | | | |
Collapse
|
20
|
Almekhlafi M, Eesa M, Menon B, Demchuk A, Goyal M. E-076 Imaging to endovascular recanalization in less than an hour is feasible. J Neurointerv Surg 2012. [DOI: 10.1136/neurintsurg-2012-010455c.76] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Eesa M, Almekhlafi M, Menon B, Wong J, Demchuk A, Goyal M. P-031 Mechanical thrombectomy with the solitaire device: is there a learning curve toward achieving rapid recanalization times?: Abstract P-031 Figure 1. J Neurointerv Surg 2012. [DOI: 10.1136/neurintsurg-2012-010455b.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
22
|
Bhangui P, Mohanka R, Saigal S, Kakodkar R, Rastogi A, Goja S, Menon B, Saraf N, Mohan N, Soin A. 6 tuberculosis and living donor liver transplantation-a 7-year experience from India. J Clin Exp Hepatol 2011; 1:135-6. [PMID: 25755334 PMCID: PMC3940131 DOI: 10.1016/s0973-6883(11)60143-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
23
|
Ramachandra S, Saigal S, Saraf N, Kakodkar R, Mohanka R, Goja S, Rastogi A, Menon B, Baijal S, Soin A. 23 postliver biopsy arterioportal fistula in living donor liver transplant-a case report. J Clin Exp Hepatol 2011; 1:143-4. [PMID: 25755352 PMCID: PMC3940248 DOI: 10.1016/s0973-6883(11)60160-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
24
|
Menon KMJ, Menon B, Wang L, Gulappa T, Harada M. Molecular regulation of gonadotropin receptor expression: relationship to sterol metabolism. Mol Cell Endocrinol 2010; 329:26-32. [PMID: 20570710 PMCID: PMC2946426 DOI: 10.1016/j.mce.2010.05.014] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2010] [Revised: 05/26/2010] [Accepted: 05/26/2010] [Indexed: 11/21/2022]
Abstract
We have identified a specific LHR mRNA binding protein that selectively binds to the polypyrimidine-rich bipartite sequence in the coding region of the LHR mRNA and accelerates its degradation. This process has been shown to be one of the mechanisms that is responsible for the loss of the steady-state levels of LHR mRNA following the preovulatory LH surge or the down regulation of the receptor in response to the administration of a pharmacological dose of LH or hCG. The trans factor, designated as the LHR mRNA binding protein (LRBP), was purified and its identity was established as being mevalonate kinase, an enzyme involved in cholesterol biosynthesis. When mevalonate kinase expression was abolished by treating cultured luteal cells with 25-hydroxycholesterol, the ability to undergo LH-induced down regulation of LHR mRNA was completely abrogated. Examination of the crystal structure of mevalonate kinase coupled with mutagenesis of the critical residues in the catalytic site revealed that the catalytic site is in close proximity to the LHR mRNA binding site. Further studies revealed that mevalonate kinase causes LHR mRNA degradation by acting as a translational suppressor by forming an untranslatable ribonucleoprotein (RNP) complex which is then targeted for degradation. These studies show that LHR expression in the ovary is regulated by a post-transcriptional mechanism mediated by mevalonate kinase thereby linking LHR expression with cholesterol metabolism.
Collapse
Affiliation(s)
- K M J Menon
- Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI 48109-0617, United States.
| | | | | | | | | |
Collapse
|
25
|
Goyal M, Menon B, Hill M, Coutts S, Demchuk A. O-028 Effect of baseline CT scan appearance and time to recanalization on clinical outcomes in endovascular thrombolysis of acute ischemic strokes. J Neurointerv Surg 2010. [DOI: 10.1136/jnis.2010.003244.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
26
|
Menon B, Davis M, Herrera C, Eesa M, Demchuk A, Goyal M, Archer D, Hill M. P-005 Anesthetic considerations and the role of blood pressure management in the endovascular treatment of acute ischemic stroke. J Neurointerv Surg 2010. [DOI: 10.1136/jnis.2010.003236.5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Iqbal A, Aggarwal B, Menon B, Kulshreshtha R. Talc granulomatosis mimicking sarcoidosis. Singapore Med J 2008; 49:e168-e170. [PMID: 18695849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Pulmonary disease due to talc, a group of hydrous magnesium silicates, is almost exclusively encountered secondary to occupational exposure or intravenous drug abuse. Talcosis or talc pneumoconiosis is one of the rarer forms of silicate-induced lung disease. It is seen in workers exposed during its production, and occasionally, in users of cosmetic talc and in intravenous drug addicts. Very often, the history of exposure is not recognised by the patient, and it is only the finding of granulomatous cellular interstitial lesions containing birefringent crystals which indicates considerable talc exposure. We report a 38-year-old woman who was initially diagnosed with sarcoidosis, until a bronchoscopic biopsy revealed the presence of numerous foreign body giant cells and birefringent particles forming non-caseating granulomas. There was no history of occupational exposure to talc or intravenous drug abuse. The patient responded to oral corticosteroid treatment. Talcosis is generally considered to be relatively benign.
Collapse
Affiliation(s)
- A Iqbal
- Department of Respiratory Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi 110007, India
| | | | | | | |
Collapse
|
28
|
Menon B, Gurnani M, Aggarwal B. Comparison of outpatient visits and hospitalisations, in patients with chronic obstructive pulmonary disease, before and after influenza vaccination. Int J Clin Pract 2008; 62:593-8. [PMID: 18284444 DOI: 10.1111/j.1742-1241.2007.01641.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVE To determine the effectiveness of influenza vaccination on acute respiratory illness (ARI) and on acute exacerbation of chronic obstructive pulmonary disease (AECOPD) during a 2-year study conducted prior to and after influenza vaccination in patients with chronic obstructive pulmonary disease (COPD). MATERIALS AND METHODS Eighty-seven male patients with COPD were stratified on the basis of their forced expiratory volume in 1 s (FEV(1)) as having mild, moderate and severe COPD. These patients were evaluated for a total duration of 2 years; 1 year prior to vaccination and for a period of 1 year following influenza vaccination. The vaccine (split virion, inactivated) composed of A/New Caledonia/20/99 (H1N1); A/California/7/2004(H3N2) and B/Shanghai/361/2002 strains all with 15 mug of haemagglutinin in each 0.5 ml dose. MEASUREMENTS The number of episodes and severity of ARI and AECOPD, classified as outpatient treatment, hospitalisation and requirement of mechanical ventilation, for a period of 1 year before and 1 year after influenza vaccination were recorded. RESULTS The incidence of ARI and AECOPD was 28.6 per 100 person-years prior to vaccination and 9.7 per 100 person-years postvaccination [relative risk (RR) 0.33; p = 0.005). Among the exacerbations because of natural infections prior to vaccination the incidences were 16.12, 42.1 and 33.14 per 100 person-years in the patients with mild, moderate and severe COPD respectively. These were significantly lower following vaccination with the incidences being 6.5, 18.5 and 8.42 per 100 person-years in the same subgroup of patients. Vaccine effectiveness in patients with mild COPD was 60% RR, 0.4 (p = 0.26); in patients with moderate COPD was 60% RR, 0.4 (p = 0.56); and in patients with severe COPD was 75% RR, 0.25 (p = 0.02). The total number of outpatient visits and hospitalisations before vaccination was eight and 14, respectively for a duration of 1 year in the total 87 patients with COPD being studied which decreased significantly to four outpatient visits and four hospitalisations postvaccination (p = 0.02). The overall effectiveness of influenza vaccination was 67%. CONCLUSIONS Influenza vaccination is highly effective in the prevention of ARI. Maximum protection was found to be in patients with severe COPD. Influenza vaccination in patients is associated with fewer outpatient visits and fewer hospitalisations.
Collapse
Affiliation(s)
- B Menon
- Allergy and Applied Immunology, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India
| | | | | |
Collapse
|
29
|
Menon B, Vengamma B. A woman with language disturbance. Postgrad Med J 2005; 81:341-2. [PMID: 15879052 PMCID: PMC1743268 DOI: 10.1136/pgmj.2004.022855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- B Menon
- Sri Venkateswara Institute of Medical Science, Tirupati, India.
| | | |
Collapse
|
30
|
Menon B, Kumar NA, Sudhakaran PR. Modulation of alpha1beta1 integrin mediated adhesion of hepatocytes to collagen IV and laminin by divalent cations. INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS 2001; 38:159-65. [PMID: 11693378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Cell matrix interactions play a critical role in hepatic development and regeneration after acute injury. These interactions are mediated by transmembrane receptors belonging mainly to the integrin family. We have tried to assess the role of divalent cations in mediating attachment of hepatocytes to matrix proteins like collagen IV (Col IV) and laminin (Ln). The three cations examined viz. Ca2+, Mg2+ and Mn2+ showed attachment promoting activity. Since alpha1beta1 integrin is a common receptor for col IV and LN in liver, the effect of cations in its binding to these matrix proteins was studied. Although cations in general enhanced the binding, different cations exhibited differential effect in promoting the binding for different ligands. Mg2+ ions were more effective in promoting the binding of alpha1beta1 integrin to col IV but Ca2+ proved to be more effective one for Ln. Kinetic analysis of binding in dot blot assays using different concentrations of cations showed that while Mg2+ was active at low concentrations Ca2+ and Mn2+ promoted the binding more at higher concentrations. Absence of competitive effect in binding studies showed that they bind at different sites on the receptor. Differential effects of cations in promoting the binding of alpha1beta1 integrin to Col IV and Ln suggest that changes in level of diffusible cations can modulate affinity of the common receptor alpha1beta1 integrin to its ligands and can influence adhesion of hepatic cells to different matrix proteins during hepatic development and regeneration.
Collapse
Affiliation(s)
- B Menon
- Department of Biochemistry, University of Kerala, Kariavattom, Trivandrum, India
| | | | | |
Collapse
|
31
|
Suresh MV, Menon B, Indira M. Effects of exogenous vitamin C on ethanol toxicity in rats. Indian J Physiol Pharmacol 2000; 44:401-10. [PMID: 11214494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The effect of a mega dose of ascorbic acid (200 mg/100 g body wt.) on alcohol-induced toxicity in rats was evaluated. In rats administered alcohol and ascorbic acid, malondialdehyde (MDA), hydroperoxide and conjugated dienes decreased in comparison with that given alcohol alone. The reduced activities of scavenging enzymes, e.g. superoxide dismutase (SOD) and catalase, in ethanol-administered rats were also enhanced by the co-administration of ascorbic acid and ethanol. Co-administration of ethanol and ascorbic acid reduced phospholipids and MDA levels of the erythrocyte membrane in comparison with that of the ethanol fed rats. The reduction in the activities of glutamic oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), gamaglutamyl transpeptidase (GGT) and the decrease in triglycerides levels also clearly showed the protective action of ascorbic acid in reducing ethanol induced toxicity.
Collapse
Affiliation(s)
- M V Suresh
- Department of Biochemistry, University of Kerala, Thiruvananthapuram-695 001
| | | | | |
Collapse
|
32
|
Menon B, Sudhakaran PR. Actin binds to the cytoplasmic tail of alpha 1 subunit of integrin in hepatocytes. Indian J Biochem Biophys 2000; 37:81-5. [PMID: 10983418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
alpha 1 beta 1-Integrin is a common receptor for laminin and collagen IV on hepatocytes. The interactions of intracellular domain of integrins with cytoplasmic elements are critical in the initiation and transduction of signals. In order to understand the nature of cytoplasmic components that can interact with cytoplasmic domain of alpha 1 integrin, cytoplasmic extracts of monolayers of rat hepatocytes were subjected to chromatography over an affinity column prepared by coupling a 60-mer synthetic cytoplasmic tail of alpha 1 subunit. SDS-PAGE analysis of the eluate showed the presence of a 47 kDa protein. Dot-Blot assay using radio-iodinated 47 kDa protein showed the binding of the protein to 60-mer C tail in a concentration dependent manner. Immunoblot analysis using specific antibodies showed that the 47 kDa protein is actin.
Collapse
Affiliation(s)
- B Menon
- Department of Biochemistry, University of Kerala, Kariavattom, Trivandrum, India
| | | |
Collapse
|